These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20310015)

  • 1. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study.
    Yamamoto T; Umegae S; Matsumoto K
    Inflamm Bowel Dis; 2010 Nov; 16(11):1905-11. PubMed ID: 20310015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.
    Tanaka T; Okanobu H; Yoshimi S; Murakami E; Kogame A; Imagawa H; Numata Y; Kuga Y; Moriya T; Ohya T; Kajiyama G
    Dig Liver Dis; 2008 Sep; 40(9):731-6. PubMed ID: 18387860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.
    Shimoyama T; Yamamoto T; Umegae S; Matsumoto K
    BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings.
    Yamamoto T; Saniabadi AR; Umegae S; Matsumoto K
    Inflamm Bowel Dis; 2006 Aug; 12(8):719-26. PubMed ID: 16917227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis.
    Nakano R; Iwakiri R; Ikeda Y; Kishi T; Tsuruoka N; Shimoda R; Sakata Y; Yamaguchi K; Fujimoto K
    J Gastroenterol Hepatol; 2013 Feb; 28(2):303-8. PubMed ID: 23339387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice.
    Iida T; Ikeya K; Kato M; Abe J; Yamamoto M; Watanabe F; Sugimoto K; Hanai H
    Digestion; 2017; 96(2):119-126. PubMed ID: 28796990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    Tanaka T; Sugiyama S; Goishi H; Kajihara T; Akagi M; Miura T
    BMC Gastroenterol; 2013 Aug; 13():130. PubMed ID: 23961883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy.
    Sagawa T; Kakizaki S; Tomizawa T; Nakayama T; Tanaka H; Tojima H; Sato K; Kusano M; Okamura S; Yamada M
    Colorectal Dis; 2016 Jul; 18(7):696-702. PubMed ID: 26748553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.
    De Cassan C; Savarino E; Marson P; Tison T; Hatem G; Sturniolo GC; D'Incà R
    World J Gastroenterol; 2014 Dec; 20(45):17155-62. PubMed ID: 25493030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy.
    Li N; Mao J; Tang H; Zhu L; Tan X; Bi J; Wu H; Chen X; Wang Y
    J Clin Apher; 2020 Aug; 35(4):271-280. PubMed ID: 32378240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission.
    Shi HY; Chan FK; Tsang SW; Hui YT; Sze SF; Ching JY; Chung T; Iu CY; Lo FH; Shan EH; Li MK; Wu JC; Sung JJ; Ng SC
    Inflamm Bowel Dis; 2015 Apr; 21(4):840-6. PubMed ID: 25738375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis.
    Yamamoto T; Iida T; Ikeya K; Kato M; Matsuura A; Tamura S; Takano R; Tani S; Osawa S; Sugimoto K; Shimoyama T; Hanai H
    Clin Transl Gastroenterol; 2018 Jul; 9(7):170. PubMed ID: 29977035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte/Monocyte Adsorptive Apheresis in Moderate to Severe Ulcerative Colitis--Effective or Not?
    Kruis W; Nguyen P; Morgenstern J
    Digestion; 2015; 92(1):39-44. PubMed ID: 26112696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.
    Kamikozuru K; Fukunaga K; Hirota S; Hida N; Ohda Y; Yoshida K; Yokoyama Y; Tozawa K; Kawa K; Iimuro M; Nagase K; Saniabadi AR; Nakamura S; Miwa H; Matsumoto T
    Clin Exp Immunol; 2009 May; 156(2):320-7. PubMed ID: 19292766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study.
    Yamamoto T; Umegae S; Matsumoto K
    J Gastroenterol; 2011 Aug; 46(8):1003-9. PubMed ID: 21681409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
    Yoshino T; Nakase H; Matsuura M; Matsumura K; Honzawa Y; Fukuchi T; Watanabe K; Murano M; Tsujikawa T; Fukunaga K; Matsumoto T; Chiba T
    Digestion; 2011; 84(1):3-9. PubMed ID: 21311190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.
    D'Ovidio V; Aratari A; Viscido A; Marcheggiano A; Papi C; Capurso L; Caprilli R
    Dig Liver Dis; 2006 Jun; 38(6):389-94. PubMed ID: 16569521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes.
    Yoshimura N; Tadami T; Kawaguchi T; Sako M; Yoshimoto H; Yamaka T; Takazoe M
    J Gastroenterol; 2012 Jan; 47(1):49-55. PubMed ID: 21915624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study.
    Yokoyama Y; Watanabe K; Ito H; Nishishita M; Sawada K; Okuyama Y; Okazaki K; Fujii H; Nakase H; Masuda T; Fukunaga K; Andoh A; Nakamura S
    Cytotherapy; 2015 May; 17(5):680-8. PubMed ID: 25804800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.